1. Home
  2. Blog
  3. UPSC

Zosurabalpin: New Antibiotic Against Drug-Resistant Bacterium

Why is it in the news?

  • Researchers have made a significant breakthrough in antibiotic discovery with the identification of a new class named ‘Zosurabalpin.’
  • This antibiotic is specifically designed to combat the drug-resistant bacterium, Acinetobacter baumannii, particularly the carbapenem-resistant strain known as CRAB.

More about the news

  • Zosurabalpin is characterized as an antibody demonstrating efficacy against conditions induced by CRAB, such as pneumonia and sepsis, particularly observed in mouse models.
  • The antibiotic is derived from a tethered macrocyclic peptide (MCP), a class of molecules.
  • Scientists identified this MCP for its selective lethality towards A. baumannii.
  • Further optimization of the MCP was undertaken to enhance its efficacy and tolerability, leading to the creation of Zosurabalpin.
  • Zosurabalpin operates through a previously unknown mode of action.
  • It inhibits the transport of lipopolysaccharide (LPS) molecules within the bacterium. This inhibition is achieved by blocking a complex of proteins responsible for LPS transport.
  • LPS transport is crucial for the construction of the outer-membrane structure in Gram-negative bacteria.
  • The blocking of LPS transport disrupts the normal functioning of the bacterium, leading to an abnormal accumulation of LPS within the bacterial cell. The abnormal build-up of LPS disrupts the bacterium’s cellular functions, ultimately causing its death.
  • Zosurabalpin has demonstrated high efficacy against a wide range of clinically tested samples of CRAB in laboratory settings.
  • This promising efficacy holds potential for addressing the challenge posed by drug-resistant strains of Acinetobacter baumannii.

Get free UPSC Updates straight to your inbox!

Get Updates on New Notification about APPSC, TSPSC and UPSC

Get Current Affairs Updates Directly into your Inbox

Discover more from AMIGOS IAS

Subscribe now to keep reading and get access to the full archive.

Continue reading